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Objective: The aim of this study was to evaluate the effectiveness of mature red cell and retic-
ulocyte parameters to identify three conditions: iron deﬁciency anemia, anemia of chronic
disease, and anemia of chronic disease associated with absolute iron deﬁciency.
Methods: Peripheral blood cells from 117 adult patients with anemia were classiﬁed accord-
ing to iron status, inﬂammation, and hemoglobinopathies as: iron deﬁciency anemia (n = 42),
anemia of chronic disease (n = 28), anemia of chronic disease associated with iron deﬁciency
anemia (n = 22), and heterozygous -thalassemia (n = 25). The percentage of microcytic eryth-
rocytes, hypochromic erythrocytes, and the levels of hemoglobin in both reticulocytes and
mature red cells were determined. Receiver operating characteristic analysis was used to
evaluate the accuracy of the parameters in differentiating anemia.
Results: There was no difference between the groups of iron deﬁciency and anemia of chronic
disease associated with absolute iron deﬁciency for any of the parameters. The percentage
of  hypochromic erythrocytes was the best parameter to identify absolute iron deﬁciency
in  patients with anemia of chronic disease (area under curve = 0.785; 95% conﬁdence inter-
val:  0.661–0.909 with sensitivity of 72.7%, and speciﬁcity of 70.4%; cut-off value 1.8%). The
formula microcytic erythrocyte count minus hypochromic erythrocyte count was very accu-
rate to differentiate iron deﬁciency anemia from heterozygous -thalassemia (area under
curve = 0.977; 95% conﬁdence interval: 0.950–1.005 with a sensitivity of 96.2%, and speciﬁcity
of  92.7%; cut-off value 13.8).
Conclusion: The erythrocyte and reticulocyte indices are moderately good to identify absolute
iron deﬁciency in patients with anemia of chronic disease.©  2015 Associac¸ão Bra
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Introduction
New automated blood cell analyzers can provide informa-
tion about individual cell characteristics, such as hemoglobin
content of reticulocytes, hemoglobin content of mature eryth-
rocytes, and percentages of microcytic erythrocytes and
hypochromic cells. These parameters have been used in
the diagnosis of iron deﬁciency anemia (IDA), -thalassemia
(-Thal),1–3 and anemia of chronic disease (ACD).4,5 The differ-
entiation between these three conditions is very important as
the clinical approach is different in each particular diagnosis.
As reticulocytes have a normal life span of one or two days,
information concerning the hemoglobin content of young
red cells is a good indication of iron availability and an
early marker of iron-deﬁciency erythropoiesis.6 Reticulocyte
hemoglobin equivalent (Ret-He) reﬂects real-time informa-
tion on the synthesis by young erythrocytes in bone marrow.
Other available parameters are the percentage of red cells with
Hb content equivalent to or less than 17 pg (%HypoHe), and
the percentage of red cells with a volume less than 60 fL (%
MicroR),1 which corresponds to a sub-population of mature
red cells exhibiting evidence of insufﬁcient iron content.
A mathematical formula using %MicroR and %HypoHe
(MHe) proposed by Urrechaga et al.7 tested discriminant
indices in healthy individuals, -Thal and IDA patients. A
sensitivity of 97.4% and speciﬁcity of 97.1% was reported in
differentiating -Thal from mild IDA.
Anemia associated with chronic inﬂammation, infection
or malignancy is the most common anemia in hospitalized
patients. Although stainable iron is present in bone marrow,
elevated levels of inﬂammatory cytokines interfere in erythro-
poiesis leading to a hyporegenerative anemia and defective
iron incorporation into erythrocyte progenitors. Reduced con-
centrations of circulating iron and normal or increased iron
stores characterize the state of functional iron deﬁciency.8
Anemia of inﬂammation can be associated with abso-
lute iron deﬁciency (ACD combi) generally in patients with
inﬂammatory disease and chronic blood loss. Differentiation
between ACD and ACD combi is clinically important, but in the
clinical practice, differentiation is difﬁcult using conventional
biomarkers such as ferritin concentration and transferrin
saturation.9 The soluble transferrin receptor/log ferritin ratio
may be useful in distinguishing ACD from ACD combi.10
The aim of this study was to analyze the effectiveness of
new laboratory parameters related to mature red blood cells
and reticulocytes to differentiate three conditions related to
iron deﬁciency: IDA, ACD and ACD combi. Moreover, the per-
formance of these parameters was tested to distinguish IDA
from -Thal, two common causes of microcytic anemia.
Methods
This project was approved by the Ethics Committee of the Fac-
ulty of Medical Sciences, Universidade Estadual de Campinas
(UNICAMP), São Paulo, Brazil. All samples were selected from
routine collections and informed consent was waived.
Peripheral blood samples from 117 adult patients with
anemia (Hb < 12.0 g/dL for women and Hb < 14.0 g/dL for men)r. 2 0 1 5;3 7(2):77–81
were selected from routine workload. Blood analysis had been
requested by general practitioners, in general to investigate
anemia.
Patients were classiﬁed according to iron status analy-
sis (commercial kits from Roche Diagnostics Germany): IDA
when serum iron (SI) levels were <45 mg/dL for men  and
<30 mg/dL for women; percentage transferrin saturation (%TS)
<15%; serum ferritin (SF) <30 g/L for men  and <13 g/L for
women.
Patients were classiﬁed as ACD when SI levels were nor-
mal  or reduced (40–160 mg/dL and 30–160 mg/dL for men  and
women, respectively), %TS normal or decreased (30–50%),
normal or high SF (30–400 g/L and 13–150 g/for men  and
women, respectively) and C-reactive protein (C-RP) > 5 mg/dL
(Tina-Quant C-Reactive Protein, Roche Diagnostics, Germany).
Soluble transferrin receptor (sTfR) levels (Roche Diag-
nostics, Germany) were measured in all samples, and the
sTfR/log ferritin ratio was used to identify iron deﬁciency in
patients with ACD. Patients with ACD having a sTfR/log fer-
ritin ratio > 2.06 or sTfR > 3.71 g/mL (cut-off values indicative
of iron deﬁciency in our laboratory) were classiﬁed as ACD
combi.
Twenty-six patients had the diagnosis of -Thal according
to the hemoglobin A2 level determined by high performance
liquid chromatography (HPLC- Variant II – Hemoglobin Testing
System, Bio-Rad Laboratories, Inc., CA, USA).
Patients with -Thal associated with other kinds of anemia,
patients with reticulocytosis or pancytopenia, individuals who
had received transfusions within the previous three months,
and patients on iron replacement therapy were excluded from
the study.
A control group (CG) was compounded by healthy individ-
uals with no clinical signs or symptoms of disease, including
acute inﬂammatory/infectious conditions, normal hemato-
logic ﬁndings, and C-RP < 5 mg/L. Healthy individuals were
students or laboratory staff, all of whom donated blood sam-
ples on a voluntary basis.
Determination of erythrocyte and reticulocyte parameters
was performed using the Sysmex XE-5000 automated hema-
tological analyzer (Sysmex, Kobe, Japan), which provides the
following parameters: Ret-He, %MicroR, hemoglobin content
of erythrocytes obtained from the optical counting of red blood
cells (RBC-He), and %HypoHe. The MHe index was calculated
as: %MIcroR-%HypoHe.7
Mann–Whitney test was applied to compare groups.
Receiver operator characteristic analysis (ROC) was used to
evaluate the accuracy of the parameters to differentiate
between types of anemia. The level of signiﬁcance was set
for a p-value <0.05. Data were analyzed using the SPSS statis-
tics program for Windows (version 13.0. SPSS Inc. Chicago, IL,
USA).
Results
According to adopted criteria, individuals were classiﬁed as
IDA (42 patients), -Thal (25 individuals), ACD combi (22
patients), ACD (28 patients) and CG (54 individuals).
Table 1 describes the demographic characteristics and lab-
oratorial data of the patients and the CG, and Table 2 shows
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Table 1 – Demographic characteristics and hematological data of patients and the control group.
Parameter IDA
(n = 42)
-Thal
(n  = 25)
ACD combi
(n = 22)
ACD
(n  = 28)
CG
(n  = 54)
Age (years) 42.0a,b
(16.0–82.0)
54.0a
(15.0–76.0)
65.6b
(20.0–81.0)
51.0
(17.0–82.0)
41.0
(16.0–75.0)
Gender male/female (%) 26.2/73.8 66.7/33.3 42.9/57.1 63.6/36.4 35.8/62.3
Hb (g/dL) 10.1
(6.2–13.6)
12.0
(6.9–14.7)
9.9
(7.3–12.2)
9.5
(6.6–12.8)
13.7
(12.0–16.1)
MCV (ﬂ) 75.2
(61.2–79.6)
65.7
(58.4–70.8)
74.4
(58.5–88.9)
81.1
(61.4–95.2)
87.9
(80.5–94.8)
MCH (pg) 22.5
(17.0–26.1)
20.4
(18.4–24.4)
24.2
(18.4–28.9)
26.8
(19.6–32.0)
29.1
(25.4–32.2)
RDW (%) 16.4
(13.4–21.0)
16.3
(14.0–19.0)
16.6
(13.7–28.2)
15.5
(13.3–25.6)
13.2
(12.0–15.5)
Values as medians, minimum and maximum.
IDA: iron deﬁciency anemia: -Thal: heterozygous beta-thalassemia; ACD combi: anemia of chronic disease associated with absolute iron
deﬁciency; ACD: anemia of chronic disease; CG: control group; Hb: hemoglobin; MCV: mean cell volume; MCH: mean cell hemoglobin; RDW: red
cell distribution width.
a p-value = 0.030.
b p-value = 0.023.
Table 2 – Biochemical data.
Parameters IDA
(n = 42)
-Thal
(n  = 25)
ACD combi
(n = 22)
ACD
(n  = 28)
CG
(n  = 54)
SI (mg/dL) 24.5
(7.0–73.0)
94.0
(49.0–224.0)
23.5
(12.0–99.0)
28.0
(9.0–98.0)
100.0
(49.0–185.0)
TS (%) 6.1
(1.5–15.5)
31.9
(22.4–68.2)
9.2
(4.5–25.7)
11.6
(3.0–42.2)
29.5
(17.6–50.1)
SF (g/L) 8.2
(3.2–23.4)
224.5
(66.8–1619.0)
254.5
(27.8–2000.0)
163.7
(42.1–2000.0)
59.6
(19.7–407.9)
sTfR (g/mL) 9.4
(1.4–28.8)
7.4
(2.6–25.5)
7.0
(3.5–22.4)
2.7
(0.5–6.2)
2.4
(1.6–3.8)
sTfR/log ferritin 10.4
(1.9–40.9)
2.6
(1.3–10.9)
3.4
(1.3–9.6)
1.1
(0.2–3.8)
1.3
(0.8–2.2)
Values as medians, minimum and maximum.
IDA: iron deﬁciency anemia: -Thal: heterozygous beta-thalassemia; ACD combi: anemia of chronic disease associated with absolute iron
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he iron status measurements used to classify the patients in
ifferent groups.
As expected the -Thal group had the highest %MicroR
Table 3). The %HypoHe was higher in the -Thal group com-
ared to other groups except for IDA patients. However, as
he microcytic cells were more  abundant in the -Thal group,
hen these two parameters were associated in the MHe  index,
his difference became more  evident and statistically signiﬁ-
ant.
The Mann–Whitney test identiﬁed no difference between
he IDA and ACD combi groups in respect to any parame-
er. When the ACD and ACD combi groups were compared,
he RBC-He and Ret-He were signiﬁcantly lower in ACD combi
atients (p-value = 0.016 and p-value = 0.003, respectively). Fur-
hermore, the %MicroR and %HypoHe were signiﬁcantly
igher in ACD combi patients, as was the MHe index (p-
alue = 0.001, p-value = 0.003 and p-value = 0.014, respectively).Although the ACD group had a sTFR/log ferritin ratio
elow the cut-off indicative of iron deﬁciency, the Ret-He
nd RBC-He values were signiﬁcantly lower than the CG iron, TS: transferrin saturation; SF: serum ferritin; sTfR: soluble
whereas the %HypoHe, %MicroR and MHe index were higher
(p-value < 0.001 for all comparisons).
The best test for differentiating IDA from -Thal was the
MHe  index (area under curve [AUC]: 0.977; 95% conﬁdence
interval [95/% CI] 0.950–1.005). A cut-off of 13.8 was very sen-
sitive (96.2%) and speciﬁc (92.7%) to identify IDA patients.
The parameter %MicroR was effective (AUC 0.886: CI: 95%
0.810–0.963) to detect iron deﬁciency with sensitivity and
speciﬁcity for values <25.0% of 84.6% and 78.0%, respectively.
The ROC curve for %HypoHe was the most effective to
differentiate between ACD and ACD combi although with a
moderate AUC (0.785: CI: 95% 0.661–0.909), sensitivity 72.7%,
and speciﬁcity 71.4% (cut-off 1.8%).
The %HypoHe was the best parameter to distinguish
between IDA and ACD (AUC: 0.835; 95% CI: 0.737–0.933). The
sensitivity and speciﬁcity of a %HypoHe < 2.45% to identify
ACD were 75.4% and 70.4%, respectively. The results of the
ROC analysis were lower for RBC-He (AUC: 0.809; 95% CI:
0.696–0.922), Ret-He (AUC: 0.780; 95% CI: 0.661–0.899), and
%MicroR (AUC: 0.785; 95% CI: 0.662–0.908).
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Table 3 – Reticulocyte and red cell indices for patients and the control group.
Parameters IDA
(n = 42)
-Thal
(n  = 25)
ACD combi
(n = 22)
ACD
(n  = 28)
CG
(n  = 54)
Ret-He (pg) 25.2
(16.9–32.6)
23.0
(21.1–30.2)
26.0b
(19.2.–37.0)
29.7c
(21.0–39.5)
35.1
(31.0–39.2)
RBC-He (pg) 23.4a
(16.7–35.3)
21.9
(18.8–26.3)
26.4b
(19.5–30.5)
28.7c
(20.8–34.7)
31.8
(28.0–34.2)
HypoHe (%) 6.2
(0.4–44.5)
9.4
(1.4–20.4)
4.4b
(1.1–31.5)
1.4c
(0.3–15.3)
0.2
(0.1–0.8)
MicroR (%) 13.5a
(0.4–48.5)
29.2
(19.3–54.2)
14.2b
(0.6–59.0)
5.55c
(1.2–48.9)
1.4
(0.5–4.0)
MHe 5.8a
(−9.8–22.2)
23.0
(8.1–34.6)
7.2b
(0–27.5)
4.05c
(0.5–36.3)
1.15
(0.3–3.7)
Values as medians, minimum and maximum.
Mann–Whitney test was applied to compare groups.
IDA: iron deﬁciency anemia: -Thal: heterozygous beta-thalassemia; ACD combi: anemia of chronic disease associated with absolute iron
deﬁciency; ACD: anemia of chronic disease; CG: control group; Ret-He: reticulocyte hemoglobin content; RBC-He: red blood cell hemoglobin
content; HypoHe: percentage of hypochromic erythrocytes; MicroR: percentage of hypochromic erythrocytes; MHe: MicroR-HypoHe index.
a p-value < 0.01 (IDA × -Thal).
b p-value ≤ 0.01 (ACD × ACD combi).
c p-value < 0.001 (ACD × CG).
The capacity of the tests to discriminate IDA from ACD
combi was not satisfactory and the AUC was less than 0.700
for all these parameters.
Discussion
The diagnostic accuracy of reticulocyte parameters has been
tested by many  authors, especially to diagnose iron deﬁ-
ciency in patients submitted to dialysis.6,10,11 Measurement
of the reticulocyte content is helpful in detecting early stages
of iron deﬁciency prior to the development of anemia.6,12,13
A reduction in reticulocyte hemoglobin has been observed
in other conditions besides iron deﬁciency, such as in
hemoglobinopathies.14,15
The effectiveness of reticulocyte parameters to diagnose
IDA and ACD was reported in other research.2,8,16 In a recent
study with geriatric patients, the authors concluded that
Ret-He is no better than classic indices, such as mean cell
hemoglobin and mean cell hemoglobin concentration, in dif-
ferentiating between IDA and ACD.5 Our results showed that,
although the Ret-He value was lower in IDA than ACD, the
accuracy of the test to distinguish both types of anemia
was moderate, and less effective compared to %HypoHe. The
potential of Ret-He was demonstrated in a study with patients
with chronic rheumatic disease and anemia. The predictive
value of RetHe was tested in response to oral iron therapy
and, according to the authors, the ﬁndings support the role
of Ret-He as a marker for iron responsiveness.17
Additional extended red blood cell parameters besides Ret-
He have been tested, such as %MicroR, and %HypoHe, and
indices generated by combining them.18 The results regarding
the differentiation between IDA and -Thal are promising,
although the optimum cut-off varies according to the popu-
18,19lation studied and the criteria adopted to classify anemia.
The MHe  index was ﬁrst proposed and tested by Urrechaga
et al. 16 The performance of this index was better (sensitivity
98.0% and speciﬁcity 95.9) than other published indices. Theauthors suggest that samples with MHe values >11.5 can be
chosen for further analysis to conﬁrm the diagnosis of tha-
lassemia; these data are coincident with our results. The MHe
index was the best parameter to discriminate IDA from -Thal,
although the cut-off value used was different from the value
described by Urrechaga et al.16 probably because patients were
not stratiﬁed according to the severity of anemia.
As far as we know, no other reports exist about the
efﬁciency of expanded erythrocyte parameters in identify-
ing patients with anemia of inﬂammation associated with
absolute iron deﬁciency. The clinical usefulness of the
determination of %Hypo has long been recognized in differ-
entiating between iron-deﬁcient and iron-sufﬁcient patients
with chronic kidney disease receiving erythropoietin stimu-
lating agents.20
The current study applied the sTfR/log ferritin ratio to iden-
tify iron deﬁciency in patients with ACD. Measurement of the
sTfR is considered a good indicator of functional iron status,
as it does not suffer any inﬂuence of systemic inﬂammation
unlike the SI, transferrin, and ferritin levels.21,22 Thus, the
transferrin receptor synthesis is stimulated when there is a
reduction of functional iron as shown by the results of this
study. Iron deﬁciency is characterized by an increase in sTfR
levels and low ferritin values, while in anemia of inﬂamma-
tion, transferrin receptor levels are slightly affected whereas
serum ferritin increases greatly.23 In the clinical practice this
differentiation is important because iron supplementation
is beneﬁcial to ACD combi patients, but may be deleteri-
ous for ACD patients. According to the results of this study,
even though the sensitivity and speciﬁcity were moderate,
the best parameter for distinguishing ACD combi from ACD
is %HypoHe, followed by MicroR. It is interesting to note that
there was no difference between the IDA and ACD combi
groups in any test, different to what was observed when ACD
was compared with IDA. In fact, the absolute iron deﬁciency
associated to ACD increases the number of microcytic and
hypochromic red cells, causing cell features similar to IDA.
ACD patients showed evidence of reduced iron availability for
oter. 
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rythropoiesis, but the disturbance of the iron metabolism
n functional iron deﬁciency was less remarkable than in the
ssociation of ACD with IDA.
In practical terms the incorporation of new cell indices
an speed up the diagnosis of IDA, -Thal and ACD, and
onsequently target more  quickly and more  precisely the sub-
equent conﬁrmatory exams in order to introduce appropriate
reatment. On the other hand, the difﬁculty in identifying
bsolute iron deﬁciency in patients with inﬂammatory con-
itions remains. Therefore, the challenge persists, and other
tudies are needed to identify a parameter with clinical deci-
ion value.
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